Vutrisiran,
does it really help with Reduced mortality and recurrent cardiovascular events in transthyretin amyloid cardiomyopathy?
research showsVutrisiran reduced the all-cause death and recurrent cardiovascular-event composite in the 655-patient multinational double-blind HELIOS-B phase 3 overall population, HR 0.72 (95% CI 0.56 to 0.93). This clear clinical-event benefit from one confirmatory trial yields B with 78 points.
ads claimThe result does not mean that death is eliminated or that every hospitalization is prevented. A 28% relative reduction in a composite endpoint must not be presented as guaranteed survival for an individual.
Useful facts when choosing a product
- Vutrisiran is a prescription siRNA that suppresses hepatic TTR production; ATTR-CM must be distinguished from hereditary ATTR polyneuropathy.
- United States labeling uses 25 mg administered subcutaneously by a health professional once every three months.
- Vitamin A supplementation at the recommended daily allowance is advised, and ocular symptoms suggesting deficiency warrant ophthalmic evaluation.
- Injection-site reactions can occur and serum vitamin A can decline, requiring prescribing oversight and monitoring.
What the research actually shows
HELIOS-B was a 655-patient multinational double-blind phase 3 trial. The overall-population primary composite of all-cause death and recurrent cardiovascular events improved, HR 0.72 (95% CI 0.56 to 0.93). Six-minute walk distance and KCCQ were secondary endpoints, not the clinical-event primary endpoint.
Why this is classified as B (78)
Clear overall-population clinical-event benefit in a 655-patient multinational double-blind phase 3 trial, tempered by one sponsor confirmatory trial, yields B with 78 points.
Counterpoint. Absolute benefit varies with disease stage, background ATTR-CM treatment, baseline tafamidis use, and genotype.
Rejudgment record. Cross-check applied — One large manufacturer-funded double-blind randomized trial met a primary composite containing hard outcomes
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced composite of death and recurrent cardiovascular events | B | HELIOS-B met its primary endpoint with HR 0.72. |
| Reduced all-cause mortality alone | B | Hierarchical secondary analysis through 42 months gave HR 0.65, but this remains one trial. |
| Reduced long-term decline in function and quality of life | B | Hierarchical secondary endpoints for six-minute walk distance and KCCQ were positive. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Fontana M et al.; HELIOS-B Trial Investigators. 2025 | Peer-reviewed original phase 3 double-blind randomized placebo-controlled trial | 655 | Alnylam Pharmaceuticals | Primary: all-cause death plus recurrent cardiovascular events | Primary endpoint met; HR 0.72 (95% CI 0.56 to 0.93), p=0.01. | Pivotal large randomized trial containing hard outcomes |
| U.S. FDA AMVUTTRA prescribing information. 2025 | Regulatory prescribing information | 326 | Regulatory document | Dosing, vitamin A, and adverse reactions | Confirmed ATTR-CM dosing and the warning for reduced vitamin A. | Supporting product and safety evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Vutrisiran x reduced mortality and recurrent cardiovascular events in ATTR-CM — Evidence Grade B·78. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/vutrisiran-attr-cm-mortality-recurrent-cardiovascular-events/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.